Skip to main content
IONS logo

Ionis Pharmaceuticals, Inc. (IONS) Stock: Price, Forecast & Analyst Target

Ionis Pharmaceuticals, Inc. (IONS) — MoonshotScore 17/100 (Weak band), calculated Nov 18, 2026. Price $27.22 (-0.62%), as of the Nov 19, 2026 trading session; market cap $4.53B.

Educational signal · not a buy or sell recommendation · How to read this

$27.22 −$0.17 (-0.62%) Market Cap $4.53B

Ionis Pharmaceuticals, Inc. · IONS · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Ionis develops and commercializes RNA-targeted medicines for rare and serious diseases, with named products on the market and a broad clinical pipeline supported by major pharmaceutical collaborations. The equity case depends on whether TRYNGOLZA and DAWNZERA can turn improving revenue into durable operating leverage while research spending remains heavy.

Price as of Nov 19, 2026

Key Statistics

17 of 100

MoonshotScore v2 · Ionis Pharmaceuticals (IONS)

Weak
Business Quality Thin (33)
Financial Safety Strained (26)
Valuation Rich (37)
Growth Durability Fading (20)
Momentum Slipping (25)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a strained balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $157M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 3 reports
  • Altman Z 0.20 · Piotroski F 3

Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IONS (57 recorded, newest six shown)
RecordedScoreBand
18Weak
18Weak
19Weak
19Weak
17Weak
17Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$27.22
Change on the day-0.62%
52-week range$26.88–$86.74
Market capitalisation$4.53B—
Shares traded on the day3.06M
Beta (volatility vs the S&P 500)0.4

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $27, high $87, latest $27. $87 $27 high $87 Oct 17, 2025 Nov 19, 2026 · $27 $73Oct 17, 2025$74Oct 31, 2025$72Nov 14, 2025$83Nov 28, 2025$81Dec 12, 2025$80Dec 26, 2025$80Jan 9, 2026$80Jan 23, 2026$87Feb 6, 2026$83Feb 20, 2026$74Mar 6, 2026$71Mar 20, 2026$75Apr 2, 2026$76Apr 17, 2026$75May 1, 2026$74May 15, 2026$77May 29, 2026$73Jun 12, 2026$81Jun 26, 2026$58Jul 10, 2026$57Jul 24, 2026$57Aug 7, 2026$60Aug 21, 2026$58Sep 4, 2026$44Sep 18, 2026$44Oct 2, 2026$43Oct 16, 2026$44Oct 30, 2026$29Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Ionis Pharmaceuticals (IONS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Weak
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ionis Pharmaceuticals (IONS), and what does it report?

Short answer · as of

Ionis is not merely a drug developer awaiting a clinical verdict. It sells RNA-targeted medicines such as TRYNGOLZA and DAWNZERA, while therapies including WAINUA, SPINRAZA and QALSODY connect its platform to a wider commercial portfolio.

Reported revenue therefore reflects a hybrid commercial-stage biotechnology business rather than demand for an isolated flagship medicine. Gross profit sits close to revenue, yet research and administrative expense still push operations into loss, so the income statement measures a transition from platform investment toward a broader marketed portfolio.

2 · Latest results

What do the latest results show for Ionis Pharmaceuticals (IONS)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $157M.

Revenue has risen across the latest reported periods after a much weaker run. The operating loss narrowed again in the latest period, although the net loss deepened.

Gross profit rose with revenue while research and administrative expense changed less, allowing incremental revenue to carry through to a smaller operating loss. The business remains unprofitable, however, and the annual record shows that higher revenue has not yet produced durable earnings.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$157M-$129M-$0.80 (diluted)
Q4 FY2025$203M-$229M-$1.42 (diluted)
Q1 FY2026$246M-$93M-$0.56 (diluted)
Q2 FY2026$268M-$115M-$0.69 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ionis Pharmaceuticals (IONS)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Liquidity is substantial relative to the observed rate of cash use, and cash and short-term investments recovered from the preceding period while remaining below earlier levels. The wider reporting window still shows an overall cash decline, and operating cash flow has swung sharply between use and generation, making any isolated period a poor guide to self-funding capacity.

Debt exceeds cash and short-term investments, leaving Ionis in net debt despite ample current liquidity. Persistent losses, negative returns, weak quality and distress screens, and demanding sales and book valuations mean slow product uptake or pipeline setbacks could leave the balance sheet carrying continued research spending.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 0.20 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Ionis Pharmaceuticals (IONS)?

Short answer · as of

Current published price targets run low $53.00 · high $115.00 · consensus $78.13 · median $82.50 against a quoted price of $27.22 (as of Nov 19, 2026).

Watch whether sequential revenue growth continues and whether gross profit again rises faster than the combined research and administrative burden. That pairing would narrow operating losses for a repeatable reason; revenue growth without expense absorption would not.

Cash conversion needs equal attention. The latest positive operating cash flow followed a severe outflow, so sustained generation alongside a stable cash balance would carry more weight than another isolated inflow.

Commercial uptake for TRYNGOLZA and DAWNZERA, progress in late-stage lipid and rare-neurology programs, and the durability of medicines developed through collaborations are the company-specific observations that can reshape the revenue profile.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Ionis Pharmaceuticals compare with its peers?

Short answer

Ionis Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Unlike biotechnology businesses supported mainly by experimental pipelines, Ionis combines marketed medicines, internal late-stage programs and collaborations with Biogen, GSK, AstraZeneca, Novartis, Roche and Metagenomi.

Its differentiation is an RNA-targeting platform applied across lipid, neurologic, cardiovascular, liver and complement-related diseases. That breadth spreads clinical exposure across distinct disease mechanisms, but the financial profile remains research-intensive: exceptionally high gross margins coexist with large operating losses and volatile cash flow.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Ascendis Pharma A/S (ASND) Named competitor$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.17 Nov 19, 2026$4.51B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.41 Nov 19, 2026$3.42B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$286.94 Nov 19, 2026$5.74B71 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.39 Nov 19, 2026$5.25B66 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.20 Nov 19, 2026$3.37B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$151.02 Nov 19, 2026$6.13B64 5-pillar Nov 18, 2026
Tango Therapeutics, Inc. (TNGX) Same industry, near in market value$21.89 Nov 18, 2026$3.71B62 5-pillar Nov 18, 2026
Moderna, Inc. (MRNA) Named competitor$199.33 Nov 19, 2026$80.7B31 5-pillar Nov 18, 2026
Ionis Pharmaceuticals (IONS) — this page$27.22$4.53B17

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$53.00 – $115.00
Consensus target
$78.13
Median target
$82.50

Consensus record · Captured .

Measured against a quoted price of $27.22 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
60
Identified insiders
18
Purchases
3
Sales
14
Other transactions
43

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IONS in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.24%$41.22MAdded +206.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ionis Pharmaceuticals (IONS)?

Read these with our analysis →

Ionis Pharmaceuticals Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

How do TRYNGOLZA and DAWNZERA change the Ionis business model?

They add named commercial medicines to a business long defined by RNA-targeted research and pharmaceutical collaborations. Their uptake can make revenue more closely connected to product demand, while the current expense base shows that commercialization has not yet displaced heavy platform investment.

What would olezarsen add beyond TRYNGOLZA?

Olezarsen is being developed for severe hypertriglyceridemia and cardiovascular disease, while TRYNGOLZA addresses familial chylomicronemia syndrome and acute pancreatitis. Its development therefore reaches a different lipid-disease setting within the same RNA-targeted franchise.

Why can Ionis report high gross profit and still lose money?

Research and administrative spending exceed the gross profit generated by current revenue. The latest periods show improving operating leverage, but the annual record still reflects sustained net losses.

Can Ionis fund its RNA-targeted pipeline from current liquidity?

Current liquidity is large relative to observed cash use, but debt exceeds cash and investments and operating cash flow is volatile. Expense discipline and sustained commercial cash generation therefore matter more than the headline liquidity balance alone.

What is the IONS stock price today?

The last price recorded for Ionis Pharmaceuticals, Inc. (IONS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the IONS price target?

The analyst consensus price target for Ionis Pharmaceuticals, Inc. (IONS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 1. What is Ionis Pharmaceuticals (IONS), and what does it report?: Business description; Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Ionis Pharmaceuticals (IONS)?: Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Ionis Pharmaceuticals (IONS)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash runway cross-check (ours); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Ionis Pharmaceuticals (IONS)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Business description; Annual revenue and net result (USD millions)
  • 5. How does Ionis Pharmaceuticals compare with its peers?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: How do TRYNGOLZA and DAWNZERA change the Ionis business model?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: What would olezarsen add beyond TRYNGOLZA?: Business description
  • FAQ: Why can Ionis report high gross profit and still lose money?: Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Annual revenue and net result (USD millions)
  • FAQ: Can Ionis fund its RNA-targeted pipeline from current liquidity?: Cash, investments and debt; Cash decline over the reported window; Cash runway cross-check (ours); Cash against market value; Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.